Nobazit tab n / 250mg film about 10 pc

Description

Composition
Active substance:
N-methyl-4-benzilkarbamidopiridiniya iodide (enisamiya iodide) (relative to anhydrous substance 100%) – 125 mg / 250 mg.
Excipients:
Lactose monohydrate (milk sugar) – 33.4 mg / 66.8 mg Microcrystalline cellulose (vivapur 101) – 10.0 mg / 20.0 mg, sucrose (refined sugar) – 9.0 mg / 18.0 mg povidone (polyvinylpyrrolidone, low molecular weight or a medical plasdon K-17) – 3.6 mg / 7.2 mg, copovidone (S-630 plasdon) – 1.4 mg / 2.8 mg crospovidone (XL-10, Polyplasdone) – 3 8 mg / 7.6 mg talc – 1.9 mg / 3.8 mg calcium stearate – 1.9 mg / 3.8 mg.
sheath: Aquarius Prime BAN314047 Yellow – 6 mg / 12 mg (Hypromellose – 3.96 mg / 7.92 mg titanium dioxide – 1.3437 mg / 2.6874 mg caprylic / caprylate (caprylic / capric triglyceride) – 0 54 mg / 1.08 mg, dye iron oxide yellow – 0.042 mg / 0.084 mg iron oxide red dye – 0.0003 mg / mg 0.0006, dye quinoline yellow – 0.114 mg / 0.228 mg).
Description:
Round biconvex film-coated tablets, yellow; in cross section the core from light yellow to yellow or yellow with a greenish tint.
Product form:
Tablets, film-coated, 125 and 250 mg.
10 tablets in blisters of PVC film and aluminum foil. 1 or 2 blisters together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to any component of the drug. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption. Deficiency of sucrase / isomaltase, fructose intolerance. Children under 18 years of age, pregnancy, lactation. The presence of allergic reactions, regardless of the nature of the allergen in history. Heavy organic lesions of liver and kidneys.
Dosage
250 mg
Indications
Treatment of influenza and other acute respiratory viral infections, including those in the complex therapy.
Interaction with other drugs
The interaction with other drugs has not been studied sufficiently.
Nobazit® enhances the effect of antibacterial and immunomodulating agents. It is expedient combination of the preparation with ascorbic acid, and other vitamins. Nobazit® also can be administered simultaneously with the use of recombinant interferon.
If you apply the above or other medications (including over the counter) before using Nobazit® drug, consult your physician.
Overdose
If overdose possible increased side effects described in the relevant section. When they occur conduct gastric lavage, symptomatic treatment.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacodynamics:
Nobazit® – antiviral agent, isonicotinic acid derivative. Effectively inhibits the action of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) by direct (inhibitory) effect on the process of virus penetration through the cell membrane.
Interferonogenic has properties, promotes the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma of 3-4.
Increases resistance to viral infections.
Reduces the clinical manifestations of acute viral intoxication, promotes reduction of disease duration.
Pharmacokinetics:
After oral administration enisamiya iodide quickly enters the blood stream, the maximum concentration in the blood observed after 2-2.5 hours after ingestion. Enisamiya iodide long and its metabolites circulate in the bloodstream (half-life of 13.5-14 hours), are metabolised in the liver and are rapidly cleared from the tissues (half-life of 2-3 hours). Output to 90-95% in the urine as metabolites.
Pregnancy and breast-feeding
Contraindicated for use during pregnancy and lactation.
Conditions of supply of pharmacies
Without a prescription.
side effects
Allergic reactions: hypersensitivity reactions including skin rash, urticaria, angioedema, pruritus.
From the digestive system: dry and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, tongue yellowing, nausea, vomiting, heartburn, stomachache, gravity in the right hypochondrium, diarrhea, bloating.
The respiratory system: dyspnea, throat irritation.
In the post-registration period observed in a few cases these side reactions include headache, dizziness, weakness, blood pressure oscillation.
If you have marked side effects indicated in the instructions or they are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Should be used with caution in patients with drug thyroid diseases, especially in hyperthyroidism.
The effect on the ability to operate vehicles, machinery
Nobazit® the drug does not affect the ability to drive vehicles and a variety of mechanical equipment.
Storage conditions
In a dry, dark place at a temperature of from 2 to 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Treatment initiated at the first signs of the disease. If after 3 days of treatment there is no improvement or symptoms are aggravated, or there are new symptoms, you should consult with your doctor. Use according to the drug only indications that the application and in those doses which are specified in the instruction.
Nobazit® taken orally after a meal with liquid of 0.5 g of 3 times a day.
The maximum single dose – 1 g daily – 2 Years
The recommended course of treatment for 5 to 7 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist